A citation-based method for searching scientific literature

Laima Tihomirova, Iveta Vaivade, Oksana Fokina, Raitis Peculis, Ilona Mandrika, Olga Sinicka, Aivars Stengrevics, Anna Krilova, Guntars Keire, Janis Petrevics, Janis Eglitis, Mihails Timofejevs, Marcis Leja. Adv Med Sci 2014
Times Cited: 2







List of co-cited articles
3 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Pathology update to the Manchester Scoring System based on testing in over 4000 families.
D Gareth Evans, Elaine F Harkness, Inga Plaskocinska, Andrew J Wallace, Tara Clancy, Emma R Woodward, Tony A Howell, Marc Tischkowitz, Fiona Lalloo. J Med Genet 2017
26
100

Genotype-phenotype correlations among BRCA1 4153delA and 5382insC mutation carriers from Latvia.
Grigorijs Plakhins, Arvids Irmejs, Andris Gardovskis, Signe Subatniece, Santa Rozite, Marianna Bitina, Guntars Keire, Gunta Purkalne, Uldis Teibe, Genadijs Trofimovics,[...]. BMC Med Genet 2011
8
100

BRCA1/2 mutation screening in high-risk breast/ovarian cancer families and sporadic cancer patient surveilling for hidden high-risk families.
Dace Berzina, Miki Nakazawa-Miklasevica, Jekaterina Zestkova, Karina Aksenoka, Arvids Irmejs, Andris Gardovskis, Dagnija Kalniete, Janis Gardovskis, Edvins Miklasevics. BMC Med Genet 2013
8
100

Genetic testing and familial implications in breast-ovarian cancer families.
Jan C Oosterwijk, Jakob de Vries, Marian J Mourits, Geertruida H de Bock. Maturitas 2014
19
50

Evaluation of the relative effectiveness of the 2017 updated Manchester scoring system for predicting BRCA1/2 mutations in a Southeast Asian country.
Winston Chew, Rajesh Babu Moorakonda, Eliza Courtney, Hazel Soh, Shao Tzu Li, Yanni Chen, Tarryn Shaw, John Carson Allen, Dafydd Gareth R Evans, Joanne Ngeow. J Med Genet 2018
2
50

Triple-negative breast cancer.
William D Foulkes, Ian E Smith, Jorge S Reis-Filho. N Engl J Med 2010
50

Mutations in 12 genes for inherited ovarian, fallopian tube, and peritoneal carcinoma identified by massively parallel sequencing.
Tom Walsh, Silvia Casadei, Ming K Lee, Christopher C Pennil, Alex S Nord, Anne M Thornton, Wendy Roeb, Kathy J Agnew, Sunday M Stray, Anneka Wickramanayake,[...]. Proc Natl Acad Sci U S A 2011
565
50

Panel Testing for Familial Breast Cancer: Calibrating the Tension Between Research and Clinical Care.
Ella R Thompson, Simone M Rowley, Na Li, Simone McInerny, Lisa Devereux, Michelle W Wong-Brown, Alison H Trainer, Gillian Mitchell, Rodney J Scott, Paul A James,[...]. J Clin Oncol 2016
110
50

PARP inhibitors: Synthetic lethality in the clinic.
Christopher J Lord, Alan Ashworth. Science 2017
846
50

Genomic profiling of breast tumours in relation to BRCA abnormalities and phenotypes.
Olafur Andri Stefansson, Jon Gunnlaugur Jonasson, Oskar Thor Johannsson, Kristrun Olafsdottir, Margret Steinarsdottir, Sigridur Valgeirsdottir, Jorunn Erla Eyfjord. Breast Cancer Res 2009
96
50

Associations of common breast cancer susceptibility alleles with risk of breast cancer subtypes in BRCA1 and BRCA2 mutation carriers.
Karoline B Kuchenbaecker, Susan L Neuhausen, Mark Robson, Daniel Barrowdale, Lesley McGuffog, Anna Marie Mulligan, Irene L Andrulis, Amanda B Spurdle, Marjanka K Schmidt, Rita K Schmutzler,[...]. Breast Cancer Res 2014
45
50

Efficacy versus effectiveness of clinical genetic testing criteria for BRCA1 and BRCA2 hereditary mutations in incident breast cancer.
Martin P Nilsson, Christof Winter, Ulf Kristoffersson, Martin Rehn, Christer Larsson, Lao H Saal, Niklas Loman. Fam Cancer 2017
13
50

The prevalence of BRCA1 mutations among young women with triple-negative breast cancer.
S R Young, Robert T Pilarski, Talia Donenberg, Charles Shapiro, Lyn S Hammond, Judith Miller, Karen A Brooks, Stephanie Cohen, Beverly Tenenholz, Damini Desai,[...]. BMC Cancer 2009
167
50

Relative contributions of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women.
E Comen, M Davids, T Kirchhoff, C Hudis, K Offit, M Robson. Breast Cancer Res Treat 2011
66
50

Inherited mutations in 17 breast cancer susceptibility genes among a large triple-negative breast cancer cohort unselected for family history of breast cancer.
Fergus J Couch, Steven N Hart, Priyanka Sharma, Amanda Ewart Toland, Xianshu Wang, Penelope Miron, Janet E Olson, Andrew K Godwin, V Shane Pankratz, Curtis Olswold,[...]. J Clin Oncol 2015
360
50

Clinical characteristics of individuals with germline mutations in BRCA1 and BRCA2: analysis of 10,000 individuals.
Thomas S Frank, Amie M Deffenbaugh, Julia E Reid, Mark Hulick, Brian E Ward, Beth Lingenfelter, Kathi L Gumpper, Thomas Scholl, Sean V Tavtigian, Dmitry R Pruss,[...]. J Clin Oncol 2002
628
50


Frequency of mutations in individuals with breast cancer referred for BRCA1 and BRCA2 testing using next-generation sequencing with a 25-gene panel.
Nadine Tung, Chiara Battelli, Brian Allen, Rajesh Kaldate, Satish Bhatnagar, Karla Bowles, Kirsten Timms, Judy E Garber, Christina Herold, Leif Ellisen,[...]. Cancer 2015
255
50

Validation of the Manchester scoring system for predicting BRCA1/2 mutations in 9,390 families suspected of having hereditary breast and ovarian cancer.
Karin Kast, Rita K Schmutzler, Kerstin Rhiem, Marion Kiechle, Christine Fischer, Dieter Niederacher, Norbert Arnold, Tiemo Grimm, Dorothee Speiser, Brigitte Schlegelberger,[...]. Int J Cancer 2014
21
50

Clinical Actionability of Multigene Panel Testing for Hereditary Breast and Ovarian Cancer Risk Assessment.
Andrea Desmond, Allison W Kurian, Michele Gabree, Meredith A Mills, Michael J Anderson, Yuya Kobayashi, Nora Horick, Shan Yang, Kristen M Shannon, Nadine Tung,[...]. JAMA Oncol 2015
201
50

Mutation detection rates associated with specific selection criteria for BRCA1/2 testing in 1854 high-risk families: A monocentric Italian study.
Jacopo Azzollini, Giulietta Scuvera, Eleonora Bruno, Patrizia Pasanisi, Daniela Zaffaroni, Mariarosaria Calvello, Barbara Pasini, Carla B Ripamonti, Mara Colombo, Valeria Pensotti,[...]. Eur J Intern Med 2016
13
50

Genetics of breast cancer: a topic in evolution.
S Shiovitz, L A Korde. Ann Oncol 2015
121
50

BRCA1 testing should be offered to individuals with triple-negative breast cancer diagnosed below 50 years.
L Robertson, H Hanson, S Seal, M Warren-Perry, D Hughes, I Howell, C Turnbull, R Houlston, S Shanley, S Butler,[...]. Br J Cancer 2012
67
50

American BRCA Outcomes and Utilization of Testing (ABOUT) study: a pragmatic research model that incorporates personalized medicine/patient-centered outcomes in a real world setting.
Joanne Armstrong, Michele Toscano, Nancy Kotchko, Sue Friedman, Marc D Schwartz, Katherine S Virgo, Kristian Lynch, James E Andrews, Claudia X Aguado Loi, Joseph E Bauer,[...]. J Genet Couns 2015
7
50

Repeated observation of breast tumor subtypes in independent gene expression data sets.
Therese Sorlie, Robert Tibshirani, Joel Parker, Trevor Hastie, J S Marron, Andrew Nobel, Shibing Deng, Hilde Johnsen, Robert Pesich, Stephanie Geisler,[...]. Proc Natl Acad Sci U S A 2003
50

Triple negative breast carcinoma and the basal phenotype: from expression profiling to clinical practice.
Leslie K Diaz, Vincent L Cryns, W Fraser Symmans, Nour Sneige. Adv Anat Pathol 2007
85
50

Breast and ovarian cancer in relatives of cancer patients, with and without BRCA mutations.
Jennifer S Lee, Esther M John, Valerie McGuire, Anna Felberg, Kimberly L Ostrow, Richard A DiCioccio, Frederick P Li, Alexander Miron, Dee W West, Alice S Whittemore. Cancer Epidemiol Biomarkers Prev 2006
29
50

Screening for BRCA1, BRCA2, CHEK2, PALB2, BRIP1, RAD50, and CDH1 mutations in high-risk Finnish BRCA1/2-founder mutation-negative breast and/or ovarian cancer individuals.
Kirsi M Kuusisto, Aleksandra Bebel, Mauno Vihinen, Johanna Schleutker, Satu-Leena Sallinen. Breast Cancer Res 2011
72
50

Phenotypic characterization of BRCA1 and BRCA2 tumors based in a tissue microarray study with 37 immunohistochemical markers.
José Palacios, Emiliano Honrado, Ana Osorio, Alicia Cazorla, David Sarrió, Alicia Barroso, Sandra Rodríguez, Juan C Cigudosa, Orland Diez, Carmen Alonso,[...]. Breast Cancer Res Treat 2005
122
50

The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2.
Sunil R Lakhani, Marc J Van De Vijver, Jocelyne Jacquemier, Thomas J Anderson, Peter P Osin, Lesley McGuffog, Douglas F Easton. J Clin Oncol 2002
581
50

Pathogenic and likely pathogenic variant prevalence among the first 10,000 patients referred for next-generation cancer panel testing.
Lisa R Susswein, Megan L Marshall, Rachel Nusbaum, Kristen J Vogel Postula, Scott M Weissman, Lauren Yackowski, Erica M Vaccari, Jeffrey Bissonnette, Jessica K Booker, M Laura Cremona,[...]. Genet Med 2016
152
50

HBOC multi-gene panel testing: comparison of two sequencing centers.
Christopher Schroeder, Ulrike Faust, Marc Sturm, Karl Hackmann, Kathrin Grundmann, Florian Harmuth, Kristin Bosse, Martin Kehrer, Tanja Benkert, Barbara Klink,[...]. Breast Cancer Res Treat 2015
28
50

X chromosomal abnormalities in basal-like human breast cancer.
Andrea L Richardson, Zhigang C Wang, Arcangela De Nicolo, Xin Lu, Myles Brown, Alexander Miron, Xiaodong Liao, J Dirk Iglehart, David M Livingston, Shridar Ganesan. Cancer Cell 2006
609
50


BRCA1 and BRCA2 mutations in women with familial or early-onset breast/ovarian cancer in the Czech Republic.
Lenka Foretova, Eva Machackova, Marie Navratilova, Hana Pavlu, Marcela Hruba, Miroslava Lukesova, Dalibor Valik. Hum Mutat 2004
25
50

Clinical, molecular and geographical features of hereditary breast/ovarian cancer in latvia.
Andris Gardovskis, Arvids Irmejs, Edvins Miklasevics, Viktors Borosenko, Marianna Bitina, Inga Melbarde-Gorkusa, Andrejs Vanags, Grzegorz Kurzawski, Janina Suchy, Bohdan Górski,[...]. Hered Cancer Clin Pract 2005
7
50

The incidence of occult ovarian neoplasia and cancer in BRCA1/2 mutation carriers after the bilateral prophylactic salpingo-oophorectomy (PBSO): A single-center prospective study.
Vilius Rudaitis, Vismantas Mikliusas, Gediminas Januska, Povilas Jukna, Ugnius Mickys, Ramunas Janavicius. Eur J Obstet Gynecol Reprod Biol 2020
2
50

High prevalence of two BRCA1 mutations, 4154delA and 5382insC, in Latvia.
Laima Tikhomirova, Olga Sinicka, Dagnija Smite, Janis Eglitis, Shirley V Hodgson, Aivars Stengrevics. Fam Cancer 2005
31
50

BRCA1 mutations in women with familial or early-onset breast cancer and BRCA2 mutations in familial cancer in Estonia.
Kristiina Tamboom, Krista Kaasik, Jelena Aršavskaja, Mare Tekkel, Aili Lilleorg, Peeter Padrik, Andres Metspalu, Toomas Veidebaum. Hered Cancer Clin Pract 2010
10
50

BRCA1 founder mutations and beyond in the Polish population: A single-institution BRCA1/2 next-generation sequencing study.
Artur Kowalik, Monika Siołek, Janusz Kopczyński, Kamila Krawiec, Joanna Kalisz, Sebastian Zięba, Beata Kozak-Klonowska, Elżbieta Wypiórkiewicz, Jowita Furmańczyk, Ewelina Nowak-Ozimek,[...]. PLoS One 2018
8
50

High frequency of pathogenic non-founder germline mutations in BRCA1 and BRCA2 in families with breast and ovarian cancer in a founder population.
J Maksimenko, A Irmejs, G Trofimovičs, D Bērziņa, E Skuja, G Purkalne, E Miklaševičs, J Gardovskis. Hered Cancer Clin Pract 2018
5
50

Targeted sequencing to discover germline variants in the BRCA1 and BRCA2 genes in a Russian population and their association with breast cancer risk.
Sergei A Solodskikh, Anna V Panevina, Maria V Gryaznova, Artem P Gureev, Olga V Serzhantova, Andrei A Mikhailov, Alexander Y Maslov, Vasily N Popov. Mutat Res 2019
2
50

Spectrum and Prevalence of Pathogenic Variants in Ovarian Cancer Susceptibility Genes in a Group of 333 Patients.
Magdalena Koczkowska, Natalia Krawczynska, Maciej Stukan, Alina Kuzniacka, Izabela Brozek, Marcin Sniadecki, Jaroslaw Debniak, Dariusz Wydra, Wojciech Biernat, Piotr Kozlowski,[...]. Cancers (Basel) 2018
17
50

Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations.
Timothy R Rebbeck, Tara M Friebel, Eitan Friedman, Ute Hamann, Dezheng Huo, Ava Kwong, Edith Olah, Olufunmilayo I Olopade, Angela R Solano, Soo-Hwang Teo,[...]. Hum Mutat 2018
111
50

Analysis of BRCA1 and BRCA2 genes in Spanish breast/ovarian cancer patients: a high proportion of mutations unique to Spain and evidence of founder effects.
Orland Díez, Ana Osorio, Mercedes Durán, José Ignacio Martinez-Ferrandis, Miguel de la Hoya, Raquel Salazar, Ana Vega, Berta Campos, Raquel Rodríguez-López, Eladio Velasco,[...]. Hum Mutat 2003
133
50

Analysis of 30 putative BRCA1 splicing mutations in hereditary breast and ovarian cancer families identifies exonic splice site mutations that escape in silico prediction.
Barbara Wappenschmidt, Alexandra A Becker, Jan Hauke, Ute Weber, Stefanie Engert, Juliane Köhler, Karin Kast, Norbert Arnold, Kerstin Rhiem, Eric Hahnen,[...]. PLoS One 2012
33
50

Non-founder BRCA1 mutations in Russian breast cancer patients.
Aglaya G Iyevleva, Evgeny N Suspitsin, Karin Kroeze, Tatiana V Gorodnova, Anna P Sokolenko, Konstantin G Buslov, Dmitry A Voskresenskiy, Alexandr V Togo, Sergey P Kovalenko, Nienke van der Stoep,[...]. Cancer Lett 2010
24
50

Founder mutations in early-onset, familial and bilateral breast cancer patients from Russia.
Anna P Sokolenko, Maxim E Rozanov, Natalia V Mitiushkina, Natalia Yu Sherina, Aglaya G Iyevleva, Elena V Chekmariova, Konstantin G Buslov, Evgeny S Shilov, Alexandr V Togo, Elena M Bit-Sava,[...]. Fam Cancer 2007
52
50

[Genotyping of BRCA1, BRCA2 and CHEK2 germline mutations in Russian breast cancer patients using diagnostic biochips].
T V Nasedkina, O E Gromyko, M A Emel'ianova, E O Ignatova, T P Kazubskaia, S M Portnoĭ, A S Zasedatelev, L N Liubchenko. Mol Biol (Mosk) 2014
1
100

High frequency and allele-specific differences of BRCA1 founder mutations in breast cancer and ovarian cancer patients from Belarus.
N V Bogdanova, N N Antonenkova, Y I Rogov, J H Karstens, P Hillemanns, T Dörk. Clin Genet 2010
31
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.